Multi-Center Study Comparing Efficacy and Safety of Frequently Modified Insulin Therapy

Inclusion Criteria: 1. 21 to 70 years of age 2. If female, must be of non-childbearing potential or have a negative urine pregnancy test at screening and using adequate method of contraception throughout conduct of the study 3. Clinical diagnosis of Type-2 diabetes for at least 1-year 4. HbA1c 7.5% to 11% inclusive 5. Total daily dose of insulin of 25 units or more (10 units if on Lantus® alone) using one of these insulin regimens: * Regimen 1 - a single injection of the long-acting insulin analog Lantus® (Glargine) per day (limited to a daily dose that is no more than 0.7 units per kg of body weight); * Regimen 2 - twice daily biphasic insulin (i.e., Humalog® Mix 75/25, NovoLog® Mix 70/30) or pre-mixed insulin (i.e., Humulin® 70/30, Novolin® 70/30); * Regimen 3 - a short-acting insulin analog (i.e., Humalog®-Lispro, NovoLog®-Aspart, Apidra®-Glulisine) before each meal and are treated with a single injection of the long-acting insulin analog Lantus® (Glargine) per day and do not utilize an insulin/carbohydrate ratio for calculating their short-acting insulin doses; or * Regimen 4 - with a short-acting insulin analog (i.e., Humalog®-Lispro, NovoLog®-Aspart, Apidra®-Glulisine) before each meal and a single injection of the long-acting insulin analog Lantus® (Glargine) per day and utilize an insulin/carbohydrate ratio for calculating their short-acting insulin doses. 6. On same insulin regimen for the previous 3-months 7. May be using other diabetes agents at a stable dose for the last 3-months 8. Signed and dated informed consent document, which contains HIPAA waiver information informing about all of the aspects of the clinical study; 9. Will regularly conduct Self-Monitored Blood Glucose. Prior to randomization must meet the following . Minimum number of tests required from all subjects: * Basal insulin subjects at least 4 fasting glucose readings/wk * Premixed insulin subjects at least 8 readings/wk * Basal-bolus insulin therapy subjects at least 16 total readings/wk 10. Willing and able to comply with the scheduled clinical study activities and glucose testing: * Basal insulin subjects at least 5 fasting glucose readings/wk * Premixed insulin subjects at least 5 pre-breakfast and 5 pre-evening meal readings/wk * Basal-bolus insulin therapy subjects at least 20 total readings/wk which include 5 readings before each of the following time points: breakfast, lunch, evening meal and bedtime. Note: All subjects may be asked to test during the night if clinically indicated. 11. Participant must have a primary care provider Exclusion Criteria: 1. History \>2 episodes of severe hypoglycemia (see definition below) in the past year, or hypoglycemic unawareness when glucose levels are ≤ 50 mg/dl; 2. Significant physical, psychological, or cognitive impairment that would prohibit adherence to the protocol at the discretion of the PI; 3. Splitting Lantus and taking Lantus twice a day 4. Severe cardiovascular disease including a history of congestive heart failure, unstable angina, myocardial infarction or stroke within the 6-months preceding enrollment; 5. Active anemia w/ hematocrit ≤ 25% in women or 30% in men; 6. Advanced kidney disease Stage 4 (eGFR \< 30 ml/min) and above 7. Active cancer or cancer in the past 2-years (except non-melanoma skin cancer) 8. History of significant liver disease including cirrhosis or elevated liver enzymes (e.g., AST and ALT greater than 3 times the upper limit of normal values). 9. BMI \> 45 kg/m2 10. Are pregnant, plan to become pregnant during the study period, or are breastfeeding. 11. Have a BGMS that cannot be downloaded.